SG11201907448RA - Macrocyclic broad spectrum antibiotics - Google Patents

Macrocyclic broad spectrum antibiotics

Info

Publication number
SG11201907448RA
SG11201907448RA SG11201907448RA SG11201907448RA SG11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA
Authority
SG
Singapore
Prior art keywords
international
pct
road
san
compounds
Prior art date
Application number
SG11201907448RA
Other languages
English (en)
Inventor
Peter Smith
Tucker Roberts
Robert Higuchi
Prasuna Paraselli
Michael Koehler
Jacob Schwarz
James Crawford
Cuong Q Ly
Emily Hanan
Huiyong Hu
Yongsheng Chen
Zhiyong Yu
Colin Michael Winship Paul
McCleod Calum
Blench Toby
Original Assignee
Rqx Pharmaceuticals Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rqx Pharmaceuticals Inc, Genentech Inc filed Critical Rqx Pharmaceuticals Inc
Publication of SG11201907448RA publication Critical patent/SG11201907448RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D245/00Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201907448RA 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics SG11201907448RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/073575 2017-02-15
CNPCT/CN2017/085075 2017-05-19
PCT/CN2018/076957 WO2018149419A1 (en) 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics

Publications (1)

Publication Number Publication Date
SG11201907448RA true SG11201907448RA (en) 2019-09-27

Family

ID=63169158

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201907448RA SG11201907448RA (en) 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics
SG10202108876TA SG10202108876TA (en) 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202108876TA SG10202108876TA (en) 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics

Country Status (23)

Country Link
US (2) US20210198316A9 (https=)
EP (2) EP4371982A3 (https=)
JP (2) JP7134177B2 (https=)
KR (1) KR102671585B1 (https=)
CN (1) CN110520413B (https=)
AU (2) AU2018222093B2 (https=)
BR (1) BR112019017003A2 (https=)
CA (1) CA3053205A1 (https=)
CL (1) CL2019002305A1 (https=)
CO (1) CO2019010001A2 (https=)
CR (2) CR20190428A (https=)
ES (1) ES2979245T3 (https=)
IL (1) IL268483B2 (https=)
MA (1) MA47514A (https=)
MX (2) MX2019009752A (https=)
MY (1) MY199461A (https=)
NZ (1) NZ779474A (https=)
PE (2) PE20191618A1 (https=)
PH (1) PH12019501904A1 (https=)
SG (2) SG11201907448RA (https=)
UA (1) UA126027C2 (https=)
WO (1) WO2018149419A1 (https=)
ZA (1) ZA201905371B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
ES2961566T3 (es) * 2019-05-28 2024-03-12 Hoffmann La Roche Antibióticos macrocíclicos de amplio espectro
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1,3-二甲基-1h-吡唑-4-羧酸的合成方法
CN116284026B (zh) * 2023-03-16 2024-05-14 天津师范大学 一种水溶性阳离子分子笼及其合成方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010381A (es) * 2010-03-09 2012-11-23 Merck Canada Inc Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama.
US9187524B2 (en) * 2010-09-15 2015-11-17 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
TWI642684B (zh) * 2011-05-27 2018-12-01 Rqx製藥股份有限公司 廣效性抗生素
KR20140140580A (ko) * 2012-03-14 2014-12-09 더 스크립스 리서치 인스티튜트 광범위 항생제 아릴로마이신 유사체
EP2913854B1 (en) * 2012-10-23 2020-05-27 Fuji Electric Co., Ltd. Semiconductor device and method for manufacturing same
CN103788176A (zh) * 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
EA201590871A1 (ru) * 2012-11-21 2015-11-30 АрКьюЭкс ФАРМАСЪЮТИКЛС, ИНК. Макроциклические антибиотики широкого спектра действия
US20190067498A1 (en) * 2017-08-28 2019-02-28 Meng Tao Light-induced aluminum plating on silicon for solar cell metallization
BR112016027232A2 (pt) * 2014-05-20 2018-06-26 Genentech Inc antibióticos macrocíclicos de amplo espectro
TWI725075B (zh) * 2015-11-20 2021-04-21 美商Rqx製藥公司 巨環廣效抗生素
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN117777229A (zh) 2017-03-27 2024-03-29 豪夫迈·罗氏有限公司 用于制备阿龙霉素环类似物的方法

Also Published As

Publication number Publication date
IL268483A (en) 2019-09-26
EP3583096A1 (en) 2019-12-25
EP3583096B1 (en) 2024-03-27
CO2019010001A2 (es) 2020-04-01
PE20191618A1 (es) 2019-11-05
CA3053205A1 (en) 2018-08-23
AU2022201724A1 (en) 2022-04-07
CN110520413A (zh) 2019-11-29
CL2019002305A1 (es) 2020-04-13
PH12019501904A1 (en) 2019-10-21
US20210198316A9 (en) 2021-07-01
KR20190127720A (ko) 2019-11-13
IL268483B2 (en) 2024-02-01
AU2022201724B2 (en) 2024-02-29
SG10202108876TA (en) 2021-09-29
US20200024309A1 (en) 2020-01-23
JP2020507564A (ja) 2020-03-12
AU2018222093B2 (en) 2022-03-31
CN110520413B (zh) 2023-02-17
RU2019126728A3 (https=) 2021-09-15
ZA201905371B (en) 2025-01-29
BR112019017003A2 (pt) 2020-04-14
MA47514A (fr) 2019-12-25
UA126027C2 (uk) 2022-08-03
AU2018222093A1 (en) 2019-08-29
PE20242298A1 (es) 2024-12-11
US20230133667A1 (en) 2023-05-04
KR102671585B1 (ko) 2024-06-04
MX2022014485A (es) 2022-12-13
AU2022201724B9 (en) 2024-03-21
MY199461A (en) 2023-10-30
NZ779474A (en) 2025-12-19
EP3583096A4 (en) 2021-01-06
JP7134177B2 (ja) 2022-09-09
EP4371982A2 (en) 2024-05-22
RU2019126728A (ru) 2021-03-16
JP2022180390A (ja) 2022-12-06
WO2018149419A1 (en) 2018-08-23
MX2019009752A (es) 2019-11-11
EP4371982A3 (en) 2024-08-21
JP7461425B2 (ja) 2024-04-03
CR20190428A (es) 2020-02-13
CR20210144A (es) 2021-05-13
NZ756220A (en) 2021-09-24
EP3583096C0 (en) 2024-03-27
IL268483B1 (en) 2023-10-01
ES2979245T3 (es) 2024-09-25

Similar Documents

Publication Publication Date Title
SG11201907448RA (en) Macrocyclic broad spectrum antibiotics
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201809229VA (en) Pharmaceutical composition
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201809751XA (en) Egfr inhibitor compounds
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201909840TA (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles